NEW YORK – Relay Therapeutics and Elevar Therapeutics on Wednesday announced an exclusive global licensing agreement for lirafugratinib (RLY-4008) in FGFR2-driven cancers.

NCI will include the multi-kinase inhibitor in the umbrella trial evaluating targeted therapy combinations in AML and MDS patients.

CMS has negotiated outcomes-based agreements for sickle cell gene therapies with the two companies on behalf of participating state Medicaid programs.